PLEIOTROPIC EFFECTS OF PRORENIN RECEPOR IN COLLECTING DUCT AND INTRARENAL RAS ACTIVATION
肾素原受体在收集管和肾内 RAS 激活中的多效性作用
基本信息
- 批准号:9306688
- 负责人:
- 金额:$ 33.86万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-09-22 至 2019-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAngiotensin IIAngiotensin II ReceptorAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsBlood PressureCREB1 geneCardiovascular DiseasesCell Culture TechniquesCell membraneCell surfaceCellsChronicChronic Kidney FailureCulture MediaCyclic AMPDataDevelopmentDiabetes MellitusDiabetic NephropathyDistalDuct (organ) structureDuctal Epithelial CellEnd stage renal failureEnzymesEquilibriumExhibitsFibrosisGene TargetingGenerationsGenesGeneticGoalsHistologicHormonesHyperglycemiaHypertensionIn VitroInactive ReninInjuryKidneyKnockout MiceLaboratoriesLeadLengthLinkMediatingMembraneMethodologyMissionMolecularMusNephronsOrganPathogenesisPathway interactionsPatientsPharmaceutical PreparationsPhysiologicalPre-EclampsiaPublic HealthReceptor ActivationRegulationRenal TissueReninRenin-Angiotensin SystemResearchRiskRisk FactorsRoleSignal TransductionSodiumSodium ChlorideSolidStreptozocinSystemTestingUnited States National Institutes of HealthWaterabsorptionbaseblood pressure regulationcell typedefined contributionepithelial Na+ channelexperimental studyin vivoinnovationknock-downmouse modelnephrogenesisnew therapeutic targetnovelnovel therapeuticspleiotropismpreventprorenin receptorpublic health relevancereceptorresponsesmall hairpin RNAurinary
项目摘要
DESCRIPTION (provided by applicant): Diabetes and hypertension are two major risk factors for chronic kidney disease. Inappropriate activation of the intrarenal renin-angiotensin system (the hormone system that regulates blood pressure and water balance, RAS) substantially increases risk and progression to renal injury. Current treatments targeting the RAS only slow, rather than halt the progression to chronic kidney disease. Therefore, we urgently need to understand the mechanisms which activate this system and lead to increased blood pressure and renal injury in order to develop new therapeutic targets to control the progression to end-stage organ damage. Our long- term goal is to define the contributions of the newly discovered prorenin receptor in the collecting duct to the pathogenesis of hypertension and renal injury and to introduce a paradigm-challenging concept which explains the interaction between the prorenin receptor and prorenin in the collecting duct which highlights the functional roles of this
interaction in the regulation of sodium reabsorption, blood pressure, and development and progression of renal fibrosis in diabetes mellitus and hypertension. Our central hypothesis is that
during hypertension and hyperglycemia, the interaction between the prorenin receptor and prorenin in the collecting duct contribute to increased blood pressure and to the development and progression to renal injury by mechanisms that are both dependent and independent of angiotensin II, the major effector hormone of the renin-angiotensin system. This hypothesis will be tested addressing the following specific aims: (1) Demonstrate that the prorenin receptor is required for the activation of prorenin produced in the collecting ducts; (2) Determine the functional consequences of the interaction between prorenin and soluble prorenin receptor in the collecting duct during angiotensin II-dependent hypertension; and (3) Demonstrate that prorenin-dependent activation of membrane bound prorenin receptor to collecting duct cells leads to renal fibrosis during Streptozotocin-induced hyperglycemia. We will attain these specific aims using a vertical and innovated approach which will include in vivo and in vitro experiments using a unique mouse model developed by our laboratory with a specific genetic deletion of the prorenin receptor in the collecting duct. Experiments will be assessed using integrated physiological, molecular and histological methodologies. The successful completion of the research proposed is of great significance because findings will provide definitive in vivo evidence of the functional role of the prorenin receptor in the collecting duct, which will providea rationale for the generation of novel drugs targeting this receptor. Understanding the mechanism of this novel pathway will be of relevance to public health because it will allow the optimization of treatment in conditions associated with augmented prorenin receptor-prorenin interaction such as hypertension, diabetes, and preeclampsia.
描述(由申请人提供):糖尿病和高血压是慢性肾脏疾病的两个主要风险因素。肾内肾素-血管紧张素系统(调节血压和水平衡的激素系统,RAS)的不适当激活大大增加了肾损伤的风险和进展。目前针对RAS的治疗只能减缓而不是阻止慢性肾脏疾病的进展。因此,我们迫切需要了解激活该系统并导致血压升高和肾损伤的机制,以开发新的治疗靶点来控制终末期器官损伤的进展。我们的长期目标是确定在集合管中新发现的前肾素受体在高血压和肾损伤的发病机制中的作用,并引入一个具有范式挑战性的概念,解释集合管中前肾素受体和前肾素之间的相互作用,强调这种相互作用的功能作用。
在糖尿病和高血压中钠重吸收、血压和肾纤维化的发展和进展的调节中的相互作用。我们的核心假设是,
在高血压和高血糖症期间,在集合管中的原肾素受体和原肾素之间的相互作用通过既依赖于又不依赖于血管紧张素II(肾素-血管紧张素系统的主要效应激素)的机制而导致血压升高和肾损伤的发展和进展。将针对以下具体目标对这一假设进行检验:(1)证明前肾素受体是激活集合管中产生的前肾素所必需的;(2)确定血管紧张素II依赖性高血压期间集合管中前肾素和可溶性前肾素受体之间相互作用的功能后果;和(3)证明在链脲佐菌素诱导的高血糖期间,膜结合的前肾素受体对集合管细胞的前肾素依赖性激活导致肾纤维化。我们将使用垂直和创新的方法来实现这些特定的目标,该方法包括使用我们实验室开发的独特小鼠模型进行体内和体外实验,该模型具有收集管中的前肾素受体的特定遗传缺失。实验将使用综合生理学、分子学和组织学方法进行评估。这项研究的成功完成具有重要意义,因为研究结果将提供明确的体内证据,证明前肾素受体在集合管中的功能作用,这将为靶向该受体的新型药物的产生提供理论依据。了解这种新途径的机制将与公共卫生相关,因为它将允许优化与增强的前肾素受体-前肾素相互作用相关的疾病(如高血压、糖尿病和先兆子痫)的治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Minolfa C Prieto其他文献
Minolfa C Prieto的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Minolfa C Prieto', 18)}}的其他基金
COVID-19 and Kidney Injury: Urinary Transcriptomics of Kidney Injury in Novel Nonhuman Primate Models of SARS-CoV-2
COVID-19 和肾损伤:SARS-CoV-2 新型非人灵长类动物模型中肾损伤的尿转录组学
- 批准号:
10453220 - 财政年份:2022
- 资助金额:
$ 33.86万 - 项目类别:
COVID-19 and Kidney Injury: Urinary Transcriptomics of Kidney Injury in Novel Nonhuman Primate Models of SARS-CoV-2
COVID-19 和肾损伤:SARS-CoV-2 新型非人灵长类动物模型中肾损伤的尿转录组学
- 批准号:
10689671 - 财政年份:2022
- 资助金额:
$ 33.86万 - 项目类别:
PLEIOTROPIC EFFECTS OF PRORENIN RECEPOR IN COLLECTING DUCT AND INTRARENAL RAS ACTIVATION
肾素原受体在收集管和肾内 RAS 激活中的多效性作用
- 批准号:
8800966 - 财政年份:2014
- 资助金额:
$ 33.86万 - 项目类别:
DISTAL NEPHRON RENIN & PRORENIN RECEPTOR IN ANG II-DEPENDANT HYPERTENSION
远端肾单位肾素
- 批准号:
8360257 - 财政年份:2011
- 资助金额:
$ 33.86万 - 项目类别:
DISTAL NEPHRON RENIN & PRORENIN RECEPTOR IN ANG II-DEPENDANT HYPERTENSION
远端肾单位肾素
- 批准号:
8167895 - 财政年份:2010
- 资助金额:
$ 33.86万 - 项目类别:
相似海外基金
Early endothelial function activation by angiotensin II receptor blockers prevents vascular damage in a model of diabetes
血管紧张素 II 受体阻滞剂早期激活内皮功能可预防糖尿病模型中的血管损伤
- 批准号:
493141 - 财政年份:2023
- 资助金额:
$ 33.86万 - 项目类别:
Clinical benefits and mechanism of action of angiotensin-II receptor blocker on Cardiovascular remodeling in patients with repaired coarctation of aorta
血管紧张素II受体阻滞剂对主动脉缩窄修复患者心血管重塑的临床疗效及作用机制
- 批准号:
10734120 - 财政年份:2023
- 资助金额:
$ 33.86万 - 项目类别:
Targeting cancer-associated fibroblasts and tumour hypoxia with angiotensin II receptor blockers
使用血管紧张素 II 受体阻滞剂靶向癌症相关成纤维细胞和肿瘤缺氧
- 批准号:
445961 - 财政年份:2021
- 资助金额:
$ 33.86万 - 项目类别:
Operating Grants
Antitumor effect of HCC and exosome microRNA by angiotensin II receptor blockers and molecular target drugs
血管紧张素II受体阻滞剂和分子靶向药物对HCC和外泌体microRNA的抗肿瘤作用
- 批准号:
19K17401 - 财政年份:2019
- 资助金额:
$ 33.86万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Pleiotropic activation of endothelial function by angiotensin II receptor blockers is crucial to their protective anti-vascular remodeling effects
血管紧张素 II 受体阻滞剂对内皮功能的多效性激活对其保护性抗血管重塑作用至关重要
- 批准号:
411570 - 财政年份:2019
- 资助金额:
$ 33.86万 - 项目类别:
Heterogeneity of Angiotensin II Receptor Blockers in the inhibition of Marfan-associated Aortic Root Dilation Independent of Blood Pressure Effects
血管紧张素 II 受体阻滞剂抑制马凡相关主动脉根部扩张的异质性,与血压影响无关
- 批准号:
391615 - 财政年份:2018
- 资助金额:
$ 33.86万 - 项目类别:
Relationship between serum EETs concentrations and cardiovascular events in patients taking angiotensin II receptor blockers
服用血管紧张素II受体阻滞剂的患者血清EETs浓度与心血管事件的关系
- 批准号:
26460229 - 财政年份:2014
- 资助金额:
$ 33.86万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The development of new angiotensin II receptor vaccine
新型血管紧张素II受体疫苗的研制
- 批准号:
25870715 - 财政年份:2013
- 资助金额:
$ 33.86万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Central GRK5 modulation of Angiotensin II receptor expression in heart failure
GRK5 对心力衰竭中血管紧张素 II 受体表达的中枢调节
- 批准号:
8531707 - 财政年份:2012
- 资助金额:
$ 33.86万 - 项目类别:
Central GRK5 modulation of Angiotensin II receptor expression in heart failure
GRK5 对心力衰竭中血管紧张素 II 受体表达的中枢调节
- 批准号:
8397394 - 财政年份:2012
- 资助金额:
$ 33.86万 - 项目类别: